使用 Histoflow 流式细胞术生成和分析高参数组织学图像
2024年6月21日
1.2K 次观看
这里描述的是一种可用于通过免疫荧光显微镜对五个或更多荧光参数进行成像的方法。概述了从这些图像中提取单细胞并通过类似流式细胞术的门控策略进行单细胞分析的分析管道，该管道可以识别组织切片中的细胞亚群。
我们的首要目标是研究免疫系统细胞和中枢神经系统内的神经胶质细胞如何促进多发性硬化症等神经系统疾病的发展和进展。免疫荧光显微镜检查是生物学科中广泛使用的标准技术，对神经科学和免疫学研究至关重要。困扰研究人员的主要问题之一是，由于传统显微镜的限制，免疫荧光显微镜通常受限于一次可以成像的探针数量。
在该协议中，我们描述了一种扩展许多显微镜一次可以成像的探针数量的方法，并提供了一个分析管道来处理信息密集的图像。该协议的优点是它可以适应许多广泛使用的显微镜并且易于执行，这将使更多的实验室可以使用多重组织学分析。
概述
本研究概述了一种使用免疫荧光显微镜成像多重荧光参数的方法，以及用于分析单细胞数据的流程。该方法增强了传统成像功能，允许识别与神经系统疾病中的免疫和胶质细胞功能相关的细胞子集。
研究的关键组成部分
科学领域
- 神经科学
- 免疫学
- 细胞生物学
背景
- 免疫荧光显微镜是神经科学和免疫学中的一种重要技术。
- 在传统显微镜中，可以同时成像的探针数量存在限制。
- 所提出的方法旨在克服这些限制，使多重组织学分析更容易实现。
研究目的
- 开发一个允许成像和分析多个荧光标签的协议。
- 创建一个支持单细胞分析的分析流程，类似于流式细胞术。
- 使我们更好地理解免疫和胶质细胞在神经系统疾病中的角色。
使用的方法
- 在染色的组织切片上使用了免疫荧光显微镜。
- 研究详细说明了设置显微镜和进行荧光补偿的分步方法。
- 图像分析包括使用软件工具分离和标记单个细胞。
- 该协议允许适应各种常用显微镜。
主要结果
- 该方法有效地区分了染色的淋巴组织中的各种细胞类型。
- 机器学习被成功用于分离紧密排列的细胞。
- 分析提供了关于组织切片中细胞群体的有意义的见解。
结论
- 该协议增强了传统免疫荧光显微镜的能力。
- 建立的流程简化了单细胞分析，使多重组织学分析更容易实现。
- 研究结果可以改善我们对神经系统疾病中涉及的细胞机制的理解。
常见问题
使用这种成像方法的优点是什么？
该方法增加了可以同时成像的荧光探针数量，提高了免疫荧光显微镜获得的数据质量。
如何实施生物模型？
生物模型涉及用多种荧光染料染色的中枢神经系统组织切片中的免疫和胶质细胞。
这种方法生成什么类型的数据？
该方法生成高分辨率图像，允许单细胞分析，揭示不同细胞群体的组成和特征。
这种方法可以适应不同类型的显微镜吗？
是的，该协议设计为可以轻松适应许多常用的荧光显微镜。
本研究的主要局限性是什么？
虽然该方法增强了成像能力，但可能存在图像分析的复杂性和对软件工具熟练使用的需求等局限性。
这项研究如何有助于理解神经系统疾病？
通过使识别和分析特定的免疫和胶质细胞子集成为可能，本研究为它们在神经系统疾病进展中的作用提供了见解。
Executive Industry Relevance
High-parameter histology imaging with histoflow cytometry addresses a critical bottleneck in immune cell profiling by enabling multiplexed spatial analysis at single-cell resolution. This capability enhances predictive confidence in target validation and mechanistic de-risking, especially for complex tissues like the CNS. The approach supports portfolio decisions by integrating spatial context with quantitative immune cell subset analysis, informing early discovery and translational research.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of immune and glial cell diversity within intact tissue architecture.
- Supports functional target validation by mapping cell subsets and their spatial interactions.
- Facilitates mechanistic de-risking through high-content, multiplexed marker analysis.
- Improves predictive confidence for target selection in neuroimmunology pipelines.
Screening & Assay Development
- Prepares validated, information-rich tissue systems for downstream screening workflows.
- Standardizes quantitative single-cell outputs using flow cytometry-like gating strategies.
- Enables reproducible profiling of cell populations across multiple experimental conditions.
- Supports scalable assay development by adapting to widely available microscope platforms.
Translational & Preclinical Research
- Aligns immune cell subset mapping with disease-relevant CNS tissue models.
- Maintains spatial and phenotypic continuity from discovery through preclinical validation.
- Enables risk-adjusted advancement by quantifying cell-type abundance and tissue interactions.
- Provides translational biomarker insights for neurological disorder research.
Pipeline & Workflow Integration
This method bridges early discovery and translational research by combining high-parameter imaging with single-cell analysis, supporting workflows from hypothesis testing to preclinical model validation.
- Discovery Biology: Advances hypothesis testing by enabling multiplexed spatial and phenotypic cell profiling.
- Screening: Delivers quantitative, reproducible single-cell data for robust assay development.
- Analytics: Provides flow cytometry-like gating and statistical outputs for comparative analysis.
- Translational Research: Connects immune cell subset data to disease-relevant tissue environments.
- Enterprise Reuse: Offers a broadly adaptable imaging and analysis pipeline for diverse tissue systems.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in immune cell studies.
- Operational Value: Standardizes multiplex imaging and analysis across platforms and teams.
- Strategic Value: Enables informed go/no-go decisions and capital-efficient portfolio management.
- Portfolio Impact: Supports risk-adjusted prioritization of CNS and immunology programs.
Implementation Considerations
- Requires expertise in immunofluorescent microscopy and spectral unmixing.
- Needs access to compatible microscopes and advanced image analysis software.
- Demands cross-team standardization of staining, imaging, and gating protocols.
- Adaptable to various tissue types but may require optimization for specific models.
- Image analysis complexity and software proficiency are practical considerations.
Biopharma FAQs
Why does null hypothesis testing matter for flow cytometry-like gating?
Null hypothesis testing ensures that observed differences in immune cell subsets identified by gating are statistically significant, supporting robust target validation and reducing false positives in early discovery.
How does independent variable isolation fit spectral unmixing workflows?
Isolating single-color controls during spectral unmixing allows precise attribution of fluorescence signals to specific markers, enabling accurate analysis of each independent variable in multiplexed tissue imaging.
What do quantitative single-cell measurements enable in CNS tissue analysis?
Quantitative single-cell measurements provide detailed profiles of immune and glial cell populations, enabling comparison across conditions and supporting mechanistic insights into disease-relevant tissue environments.
Why are replication requirements critical for cross-team histology analysis?
Replication ensures that multiplexed imaging and gating strategies yield consistent results across experiments and teams, supporting reproducibility and collaborative decision-making in biopharma R&D.
What statistical analysis capabilities are required before implementing high-parameter imaging?
Robust statistical analysis is needed to interpret high-dimensional single-cell data, validate gating thresholds, and ensure that cell subset quantification informs actionable R&D decisions.
